Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ALMS vs MPLT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MPLT Captures Overall Composite Edge (50.4 HOLD vs 43.3 HOLD), While ALMS Leads 3–2 on Growth & Valuation Pillars

MPLT Overall Winner 6-Pillar Tally: ALMS 3 – 2 MPLT (1 Tie) Matrix Metrics: ALMS 2 – 5 MPLT

As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (50.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. ALMS trades at $5.06 (N/M Forward P/E, -5744.5% operating margin) versus MPLT at $6.94 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: MPLT earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.05β · 78% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.9); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALMS vs MPLT
ALMS NASDAQ
Alumis Inc. Common Stock
Pharmaceutical Preparations
$5.06
-9.65% 1D
Market Cap $793.4M
TTM Revenue $7.4M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 20.0 Fund 51.0 Flow 67.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -45.8%), weak momentum, RSI 30
RSI-14: 29.9 · SMA20: $6.43 · SMA50: $7.12
MPLT US Equity Head-to-Head Winner
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap $392.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 78% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 64.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $7.44 · SMA50: $9.21

6-Pillar Scorecard Institutional Category Breakdown (ALMS 3 – 2 MPLT)

Columns: Metric · ALMS · MPLT
1. Valuation Multiples ALMS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 103.6x N/M
2. Growth & Scale ALMS
Revenue Growth (YoY) -37.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.4M N/A
Market Cap $793.4M $392.9M
3. Profitability & Quality ALMS
Gross Margin 100.0% N/A
Operating Margin -5744.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.7% -111.5%
4. Balance Sheet & Cash Flow MPLT
Cash Generation (TTM) -$352M -$175M
Cash Flow Margin N/A N/A
Net Cash / Leverage $27M Net Cash $70M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MPLT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 80.0% (8th %ile) 92.5% (8th %ile)
Put/Call OI Skew 4433.18x (Put-Skewed) 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALMS (2) vs MPLT (5)
Institutional Metric ALMS MPLT Criterion Row Edge
Market Capitalization
Scale
$793.4M $392.9M Larger Scale ALMS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-37.7% +0.0% Higher Growth MPLT
Operating Margin (TTM)
Profitability
-5744.5% 0.0% Higher Margin MPLT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.7% -111.5% Higher ROE ALMS
52-Week Range Position
Momentum
2% ($5–$31) 3% ($6–$40) Stronger Trend MPLT
Beta / 30D Volatility
Risk Regime
2.24β · 86% Vol 1.05β · 78% Vol Lower Realized Risk MPLT
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite MPLT
Trailing 12M Revenue (USD)
Operating Scale
$7.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 103.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$352M ($27M Net Cash) -$175M ($70M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MPLT +7.46 pp
ALMS: -17.33% · MPLT: -9.87%
3M Horizon MPLT +38.37 pp
ALMS: -79.66% · MPLT: -41.29%
6M Horizon MPLT +2.27 pp
ALMS: -76.08% · MPLT: -73.81%
1Y Horizon ALMS +47.22 pp
ALMS: -4.18% · MPLT: -51.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALMS vs MPLT. Trailing 12-month operating profitability (ALMS -5744.5% vs MPLT 0.0%) and valuation multiples (ALMS N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ALMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.4M
Gross Margin100.0%
Op. Margin-5744.5%
ROE / Fwd P/E-93.7% · N/M
MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-111.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALMS BREAKDOWN
91d in phase · OBV NEUTRAL
Current IV 80.0%
IV Percentile 8th %ile
Put/Call OI Skew 4433.18x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ALMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MPLT BREAKDOWN
144d in phase · OBV ACCUMULATION
Current IV 92.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALMS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $793.4M market capitalization and -5744.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $392.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALMS vs MPLT Key Questions & Quantitative Answers

As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (50.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. ALMS trades at $5.06 (N/M Forward P/E, -5744.5% operating margin) versus MPLT at $6.94 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MPLT earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.05β · 78% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.9); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ALMS leads the Growth & Scale pillar: ALMS posts -37.7% YoY revenue growth and +0.0% YoY earnings growth on $7.4M TTM revenue (100.0% gross margin, -5744.5% operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ALMS generates $7.4M in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, ALMS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.

ALMS screens cheaper on headline valuation multiples. ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.6x EV/Revenue (unreported FCF margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALMS (-93.7% ROE) versus MPLT (-111.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ALMS carries 80.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 4433.18x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk). By comparison, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.